Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb Company (NYSE:BMY) announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.

Bristol Myers-Squibb has a comprehensive development program underway to evaluate the potential subcutaneous administration of ORENCIA through an injection into the skin in adults with moderate to severe rheumatoid arthritis. ORENCIA is already available for the treatment of adults with moderate to severe rheumatoid arthritis. The subcutaneous program utilizes a new formulation of ORENCIA, which has been specifically designed for subcutaneous administration.

These data, from a 4-month open-label trial involving 100 patients, were presented today at the American College of Rheumatology Annual Scientific Meeting. The study showed that weekly administration of a 125 mg subcutaneous dose of ORENCIA resulted in minimal, transient immunogenicity prior to Month 4 after repeat dosing. The immunogenicity was similar whether ORENCIA was administered in combination with methotrexate, a common treatment for rheumatoid arthritis, or as a monotherapy. At Month 4, patients had no antibody response to subcutaneous ORENCIA.

“These new data assessing subcutaneous ORENCIA confirm no new safety signal, demonstrate efficacy both in combination with methotrexate and as monotherapy and show no immunogenicity with the subcutaneous formulation at 4 months,” said Peter T. Nash, M.D., associate professor, Department of Medicine, University of Queensland, Brisbane, Australia.

Of the 100 patients enrolled in the open-label study, 51 received subcutaneous ORENCIA plus methotrexate and 49 received subcutaneous ORENCIA monotherapy. ORENCIA was self-administered once weekly at a fixed dose of 125 mg in a ready-to-use pre-filled syringe.

The primary objective of the short-term open-label treatment period was to evaluate the immunogenicity of ORENCIA when used with or without methotrexate in the absence of an IV loading dose of ORENCIA.

Source:

 Bristol-Myers Squibb

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study estimates the quality of care for patients with long-term health conditions